Backs FY25 total revenue view up high single-digit percentage. The company said, “AstraZeneca (AZN) reiterates its Total Revenue and Core EPS guidance4 for FY 2025 at CER, based on the average foreign exchange rates through 2024.”
Meet Your ETF AI Analyst
- Discover how TipRanks' ETF AI Analyst can help you make smarter investment decisions
- Explore ETFs TipRanks' users love and see what insights the ETF AI Analyst reveals about the ones you follow.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on AZN:
- AstraZeneca: Strong Financial Performance and Promising Pipeline Support Buy Rating
- AstraZeneca reports Q3 core EPS $2.38, up 12% at CER
- AstraZeneca sees FY25 core EPS increasing by low double-digit percentage
- These Are the Stocks Reporting Earnings Today – November 6, 2025
- AZN Earnings Report this Week: Is It a Buy, Ahead of Earnings?